Summary:
- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Cosentyx (secukinumab) for the treatment of polymyalgia rheumatica (PMR).
- This recommendation is based on clinical evidence from the Phase III ASCENT trial, which demonstrated the drug's efficacy in maintaining sustained disease remission in patients who are refractory to or intolerant of corticosteroid therapy.